NCT04667988View on ClinicalTrials.gov

JAK2 Mutation May Predict Response and Guide First Line Treatment in Rheumatoid Arthritis

NACompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

April 1, 2020

Study Completion Date

May 1, 2020

Conditions
Response Assessment in Newly Diagnosed RA Patients at 3rd Month Was Evaluated by DAS28 and ACR in Relation to JAK Expression
Interventions
DIAGNOSTIC_TEST

JAK expression

JAK2 assessment in blood by PCR

Trial Locations (1)

Unknown

Mansoura University Hospital, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER

NCT04667988 - JAK2 Mutation May Predict Response and Guide First Line Treatment in Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter